Bicarbonate

Bicarbonate

SCHEMBL59690

O=C(O)O.O=C([O-])[O-].[K+].[Na+]

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA4 P22748 6/20 0.64
FAHD1 Q6P587 1/20 0.64
CA1 P00915 3/20 0.50
CA2 P00918 2/20 0.50
MEN1 O00255 1/20 0.50
LDHA P00338 1/20 0.50
BLM P54132 1/20 0.50
KMT2A Q03164 1/20 0.50
CA9 Q16790 1/20 0.50
LMNA P02545 2/20 0.38
CASP1 P29466 1/20 0.38
FFAR3 O14843 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL6704237 1.00 CA4 (0.64) CA4FAHD1CA1CA2MEN1
Bicarbonate SCHEMBL5309573 0.95 CA4 (0.58) CA4FAHD1CA1CA2MEN1
Bicarbonate SCHEMBL28890785 0.95 CA4 (0.58) CA4FAHD1CA1CA2MEN1
Bicarbonate SCHEMBL9442722 0.95 CA4 (0.58) CA4FAHD1CA1CA2MEN1
Bicarbonate SCHEMBL7752847 0.95 CA4 (0.58) CA4FAHD1CA1CA2MEN1
Bicarbonate SCHEMBL28537604 0.95 CA4 (0.58) CA4FAHD1CA1CA2MEN1
Bicarbonate SCHEMBL9133995 0.95 CA4 (0.58) CA4FAHD1CA1CA2MEN1
Bicarbonate SCHEMBL18042414 0.95 CA1 (0.56) CA4FAHD1CA1CA2MEN1
Bicarbonate SCHEMBL2970314 0.95 CA1 (0.56) CA4FAHD1CA1CA2MEN1
Bicarbonate SCHEMBL11309619 0.95 CA1 (0.56) CA4FAHD1CA1CA2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4387955-A1 SYNTHESIS OF BRIVARACETAM OPTIMUS DRUGS PRIVATE LIMITED (IN) 2024-06-26 EP claimed
CN-117043141-A 7-nitro-8-hydroxyquinoline derivative, preparation method and medical application thereof 江苏亚虹医药科技股份有限公司 2023-11-10 CN claimed
WO-2023076589-A1 PRETREATMENT OF LIGNOCELLULOSE USING TWO STAGE ALKALI AND MECHANICAL REFINING PROCESSES ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) 2023-05-04 WO claimed
WO-2023021363-A1 SYNTHESIS OF BRIVARACETAM OPTIMUS DRUGS PRIVATE LIMITED (IN) 2023-02-23 WO claimed
EP-3775374-B1 WRAPPING PAPER WITH USE INDICATOR FOR AEROSOL GENERATING ARTICLES DELFORTGROUP AG (AT) 2022-12-21 EP claimed
WO-2022253152-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2022-12-08 WO claimed
CN-115368412-A Method for preparing minodronic acid 扬子江药业集团北京海燕药业有限公司 2022-11-22 CN claimed
CN-214780790-U Waste incineration fly ash recycling combination device 上海东硕环保科技股份有限公司 2021-11-19 CN claimed
CN-112551557-A Waste incineration fly ash recycling combination device and use method thereof 上海东硕环保科技股份有限公司 2021-03-26 CN claimed
CN-111974386-A Carbonyl sulfide hydrolysis catalyst and preparation method thereof 济南环陶环保工程有限公司 2020-11-24 CN claimed
WO-2004074251-A1 DERIVATIVES OF AZASUGARS AS ANTICANCER AGENTS RANBAXY LABORATORIES LIMITED (IN) 2004-09-02 WO claimed
US-20030125553-A1 Process for the preparation of new antidiabetic agents DR. REDDY'S LABORATORIES LIMITED 2003-07-03 US claimed
US-6248919-B1 E.G., (2S)-2-(((5-((BUTYL(2-CYCLOHEXYLETHYL)AMINO)METHYL) -2'-METHYL(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-4-(METHYLSULFAN YL)BUTANOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR PRODRUG THEREOF. ABBOTT LABORATORIES 2001-06-19 US claimed
EP-1086140-A1 MODIFIED GELLAN GUM COMPOSITION PROCESS FOR PREPARATION OF SAME AND USE THEREOF Monsanto p.l.c. (GB) 2001-03-28 EP claimed
US-6165505-A Sterilant effervescent formulation CHEM-LINK LABORATORIES, LLC (US) 2000-12-26 US claimed
WO-1999064468-A1 MODIFIED GELLAN GUM COMPOSITION PROCESS FOR PREPARATION OF SAME AND USE THEREOF MONSANTO P.L.C. (GB) 1999-12-16 WO claimed
US-5124237-A Production of photopolymerized relief printing plates having a non-tacky surface BASF AKTIENGESELLSCHAFT (DE) 1992-06-23 US claimed
US-5118345-A High strength; contains fired carbon black, graphite, water, alkali metal phosphates, borates and carbonates J.S. STAEDTLER GMBH & CO. (DE) 1992-06-02 US claimed
US-4883573-A ULTRAFILTRATION, RECYCLING BASF AKTIENGESELLSCHAFT (DE) 1989-11-28 US claimed
US-4340253-A Preflush-lixiviant process for solution mining of uranium ore beds THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE INTERIOR (US) 1982-07-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125553-A1 Process for the preparation of new antidiabetic agents GLP1R, GPR119, SLC5A1 CA4 1525/4885FAHD1 2046/4885CA1 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.